Loading...
Header Logo
Keywords
Last Name
Institution

ARGUN AKCAKANAT

Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Akcakanat A, Meric-Bernstam F. MK-2206 window of opportunity study in breast cancer. Ann Transl Med. 2018 Nov; 6(Suppl 1):S57. PMID: 30613632.
      View in: PubMed
    2. Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477. PMID: 29093017.
      View in: PubMed
    3. Woo SU, Sangai T, Akcakanat A, Chen H, Wei C, Meric-Bernstam F. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis. 2017 Oct 09; 6(10):e385. PMID: 28991258.
      View in: PubMed
    4. Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93. PMID: 28810913.
      View in: PubMed
    5. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2016; 11(3):e0151121. PMID: 26953790.
      View in: PubMed
    6. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851. PMID: 26325287.
      View in: PubMed
    7. Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, Li Y, Do KA, Janku F, Meric-Bernstam F. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget. 2015 Aug 14; 6(23):19500-13. PMID: 25944619.
      View in: PubMed
    8. Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3). PMID: 25688104.
      View in: PubMed
    9. Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57. PMID: 25261369.
      View in: PubMed
    10. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83. PMID: 24895461.
      View in: PubMed
    11. Akcakanat A, Hong DS, Meric-Bernstam F. Targeting translation initiation in breast cancer. Translation (Austin). 2014; 2(1):e28968. PMID: 26779407.
      View in: PubMed
    12. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Ann Oncol. 2014 Jun; 25(6):1122-7. PMID: 24669015.
      View in: PubMed
    13. Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther. 2014 Jul; 22(7):1310-1319. PMID: 24569835.
      View in: PubMed
    14. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70. PMID: 24764583.
      View in: PubMed
    15. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84. PMID: 24089446.
      View in: PubMed
    16. Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 2013 Oct; 22(4):641-64. PMID: 24012393.
      View in: PubMed
    17. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat. 2013 Jan; 137(1):319-27. PMID: 23208590.
      View in: PubMed
    18. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo A. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012 Oct 26; 14(5):R138. PMID: 23102376.
      View in: PubMed
    19. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012 Oct 15; 18(20):5816-28. PMID: 22932669.
      View in: PubMed
    20. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89. PMID: 22422409.
      View in: PubMed
    21. Emerling BM, Akcakanat A. Targeting PI3K/mTOR signaling in cancer. Cancer Res. 2011 Dec 15; 71(24):7351-9. PMID: 21987725.
      View in: PubMed
    22. Singh G, Akcakanat A, Sharma C, Luyimbazi D, Naff KA, Meric-Bernstam F. The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer. 2011; 63(2):264-71. PMID: 21294052.
      View in: PubMed
    23. Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther. 2010 Oct; 9(10):2770-84. PMID: 20876744.
      View in: PubMed
    24. Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer. 2009 Sep 24; 8:75. PMID: 19778445.
      View in: PubMed
    25. Kim D, Akcakanat A, Singh G, Sharma C, Meric-Bernstam F. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors. 2009 Feb; 27(1):12-21. PMID: 19085255.
      View in: PubMed
    26. Dong J, Akcakanat A, Stivers DN, Zhang J, Kim D, Meric-Bernstam F. RNA-binding specificity of Y-box protein 1. RNA Biol. 2009 Jan-Mar; 6(1):59-64. PMID: 19098458.
      View in: PubMed
    27. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther. 2008 Jul; 7(7):1782-8. PMID: 18644990.
      View in: PubMed
    28. Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008 Jun; 112(11):2352-8. PMID: 18386830.
      View in: PubMed
    29. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66. PMID: 18310292.
      View in: PubMed
    30. Akcakanat A, Singh G, Hung MC, Meric-Bernstam F. Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun. 2007 Oct 19; 362(2):330-3. PMID: 17707343.
      View in: PubMed
    31. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, Ohashi M, Hatakeyama K. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer. 2006 Jan 01; 118(1):123-8. PMID: 16003736.
      View in: PubMed
    32. Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii H, Hatakeyama K. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004 Jul; 54(1):95-100. PMID: 15118836.
      View in: PubMed
    33. Unal M, Celik E, Akçali A, Akçakanat A. Diagnostic criteria of colospasm at barium enema examination. Acta Radiol. 2002 Nov; 43(6):629-30. PMID: 12485267.
      View in: PubMed
    34. Bozkurt MK, Agalar F, Akçakanat A. Inflammatory response to open tension-free inguinal hernioplasty versus conventional repair. Am J Surg. 2000 Jan; 179(1):76. PMID: 10737585.
      View in: PubMed
    35. Akcakanat A, Agalar F. Correlation between teaching ability and examination scores. Am J Surg. 1999 Nov; 178(5):434-5. PMID: 10612548.
      View in: PubMed
    36. Akçakanat A, Agalar F, Hayran M, Sayek I. Study of interleukin-10 and experimental acute pancreatitis. Surgery. 1997 Jun; 121(6):719-20. PMID: 9186477.
      View in: PubMed
    37. Agalar F, Cakmakçi M, Er M, Akçakanat A, Sayek I. Evaluation of trauma care in a developing country highlighted by a major aircraft accident. Eur J Emerg Med. 1997 Jun; 4(2):97-102. PMID: 9228451.
      View in: PubMed
    38. Agalar F, Akçakanat A, Hayran M, Sayek I. Pulmonary function after laparoscopic cholecystectomy in the elderly. Br J Surg. 1997 Apr; 84(4):579. PMID: 9112922.
      View in: PubMed
    39. Erratum. PLoS One. 11.
    40. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget. 6:19500-19513.
    41. Ability to generate patient-derived Breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS One. 10.
    AKCAKANAT's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description